Hipertensión portal idiopática asociada a hepatocarcinoma y colangiocarcinoma. Informe de un caso

Saman, Claudia Cavazos; Ochoa, Minerva Lazos; García, Jesús Aguirre
October 2007
Revista Medica del Hospital General de Mexico;oct-dec2007, Vol. 70 Issue 4, p189
Academic Journal
Idiopathic portal hypertension (IPH) is a very rare illness of unknown etiology, it presents a wide range of macroscopic and microscopic changes that go from a macroscopically normal liver to a multinodular, atrophic and cirrhosis-like organ; microscopically the most common changes are flebosclerosis and perivascular fibrosis of the portal system vessels. Most of the patients have splenomegalia and upper digestive tract bleeding. IPH has been reported in Japan, India and in US; there are few cases from Latin America. This is a case of a young male with IPH associated with hepatocarcinoma and cholangiocarcinoma diagnosed by autopsy. The hepatic changes represent the last spectrum of the disease. There is only another case of IPH with hepatocarcinoma reported in the literature, so this is an exceptional case.


Related Articles

  • Extensive Portal Tumor Thromhi with Portal Hypertension in an Autopsy Case of Intrahepatic Cholangiocarcinoma. Terada, Tadashi; Kida, Tetsuji; Nakanuma, Yasuni; Noguchi, Takatoshi // American Journal of Gastroenterology;Oct1992, Vol. 87 Issue 10, p1513 

    Vascular invasion is not a prominent feature of cholangiocarcinoma (CCC), in contrast to hepatocellular carcinoma (HCC), which frequently shows extensive vascular tumor thrombi. We report an autopsy case of CCC with extensive portal tumor thrombi and portal hypertension. A 57-yr-old man...

  • Pharmacological Reduction of Portal Pressure and Long-Term Risk of First Variceal Bleeding in Patients with Cirrhosis. Turnes, Juan; Garcia-Pagan, Juan Carlos; Abraldes, Juan G.; Hernandez-Guerra, Manuel; Dell'Era, Alessandra; Bosch, Jaime // American Journal of Gastroenterology;Mar2006, Vol. 101 Issue 3, p506 

    OBJECTIVES: A reduction in hepatic venous pressure gradient (HVPG) of ≥20% of baseline or to ≤12 mmHg (responders) is associated with a reduced risk of first variceal bleeding. The aim of this study was to evaluate whether this protective effect is maintained in the long term and if...

  • What's wrong with this patient? Cartwright, Brenda A.; Gillen, Patrick B. // RN;Jul2002, Vol. 65 Issue 7, p37 

    Focuses on the treatment of peristomal variceal bleeding. Cause of the bleeding; Signs and symptoms of portal hypertension; Effectiveness of treatment measures; Reference on the case of 68-year-old man with a colostomy pouch full of blood.

  • Diagnosis and Treatment of Gastrointestinal Bleeding Secondary to Portal Hypertension. Grace, Norman D. // American Journal of Gastroenterology;Jul1997, Vol. 92 Issue 7, p1081 

    Guidelines for clinical practice are intended to suggest preferable approaches to particular medical problems as established by interpretation and collation of scientifically valid research, derived from extensive review of published literature. When data are not available that will withstand...

  • Portal Hypertension Associated with Hepatocellular Carcinoma without Cirrhosis. Cooney, Thomas G.; Bauer, Donald C.; Knauer, C. Michael // American Journal of Gastroenterology;Nov1980, Vol. 74 Issue 5, p436 

    Portal hypertension associated with hepatocellular carcinoma in the absence of cirrhosis of the liver has not been clearly recognized in the past. While the incidence of this association is unknown, its occurrence does not appear to be rare. This case report describes a 49-year old male with...

  • MOLLECULAR HEPATIC STELLATE CELLS TARGETS IN ANTIFIBROTIC THERAPY. Ionescu, Alin Gabriel; Vere, Cristin Constantin; Streba, Costin Teodor; Streba, Liliana; Rogoveanu, Ion // Studia Universitatis Vasile Goldis Seria Stiintele Vietii (Life ;Jul-Sep2012, Vol. 22 Issue 3, p331 

    Hepatic stellate cells (HSC) activation as a result of liver injury, followed by their proliferation and the increase of extracellular matrix (ECM) synthesis, is the main phenomenon in the development of liver fibrosis. In case of chronic liver injury, the negative consequences generated by...

  • Reversible Decrease of Portal Venous Flow in Cirrhotic Patients: A Positive Side Effect of Sorafenib. Coriat, Romain; Gouya, Hervé; Mir, Olivier; Ropert, Stanislas; Vignaux, Olivier; Chaussade, Stanislas; Sogni, Philippe; Pol, Stanislas; Blanchet, Benoit; Legmann, Paul; Goldwasser, François // PLoS ONE;2011, Vol. 6 Issue 2, p1 

    Portal hypertension, the most important complication with cirrhosis of the liver, is a serious disease. Sorafenib, a tyrosine kinase inhibitor is validated in advanced hepatocellular carcinoma. Because angiogenesis is a pathological hallmark of portal hypertension, the goal of our study was to...

  • Surveillance programmes for early detection of hepatocellular carcinoma. Simon, Krzysztof; Serafińska, Sylwia; Pazgan-Simon, Monika // Contemporary Oncology / Wspolczesna Onkologia;2012, Vol. 16 Issue 4, p295 

    Primary hepatocellular carcinoma (HCC) is the most commonly diagnosed primary malignancy of the liver. The number of new diagnosed cases of HCC seems to be on a rise worldwide. HCC is typically diagnosed in patients with underlying liver cirrhosis (> 90% cases) regardless of aetiology; over a...

  • Extracorporeal Hepatic Resection and Autotransplantation Using Temporary Portocaval Shunt Provides an Improved Solution for Conventionally Unresectable HCC. Wen, Pei-Hung; Lin, Kuo-Hua; Chen, Yao-Li; Hsieh, Chia-En; Ko, Chih-Jan; Kuo, Shou-Jen // Digestive Diseases & Sciences;Dec2013, Vol. 58 Issue 12, p3637 

    No abstract available.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics